In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Faiqa MudassarTranslational Radiation Biology and Oncology Laboratory, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.ORCID 0000-0001-7070-9590 Kristina M CookTranslational Radiation Biology and Oncology Laboratory, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.ORCID 0000-0002-0503-7166 Neha BalTranslational Radiation Biology and Oncology Laboratory, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.
Joey LaiWestmead Research Hub Core Facilities, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.
Brian GlossWestmead Research Hub Core Facilities, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.
Holly P McEwenCancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia.ORCID 0000-0002-8233-1553 Ryan J DuchatelCancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia.ORCID 0000-0002-3651-7672 Geraldine M O'NeillFaculty of Medicine and Health, Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia.
Harriet GeeTranslational Radiation Biology and Oncology Laboratory, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.ORCID 0000-0001-7397-8585 Han ShenTranslational Radiation Biology and Oncology Laboratory, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.ORCID 0000-0003-2435-2150 Eric HauTranslational Radiation Biology and Oncology Laboratory, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.
Funding
Cancer Institute NSW Career Development FellowshipCure Brain Cancer FoundationNSW HealthSydney West Radiation Oncology NetworkThe Cure Starts NowThe DIPG CollaborativeThe Mark Hughes Foundation
6 · The paper itselfAbstract
Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brain tumor. Radiotherapy remains the standard of care, but tumors recur due to radioresistance. Tumor hypoxia contributes to radioresistance, and evidence of oxidative metabolism and hypoxia-associated transcriptomic programs suggests that hypoxia may be relevant in DIPG. We therefore investigated the FDA-approved mitochondrial inhibitor atovaquone as a strategy to target oxidative metabolism and enhance radiation response in DIPG.
Indexed as
diffuse intrinsic pontine gliomamitochondrial inhibitionoxygen consumption rateradiation
Identifiers
PMID42192913
PMCPMC13204253
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390